Literature DB >> 29691251

NFATc1 Promotes Antitumoral Effector Functions and Memory CD8+ T-cell Differentiation during Non-Small Cell Lung Cancer Development.

Lisanne Heim1, Juliane Friedrich1, Marina Engelhardt1, Denis I Trufa2, Carol I Geppert3, Ralf J Rieker3, Horia Sirbu2, Susetta Finotto4.   

Abstract

Nuclear factor of activated T cells 1 (NFATc1) is a transcription factor activated by T-cell receptor (TCR) and Ca2+ signaling that affects T-cell activation and effector function. Upon tumor antigen challenge, TCR and calcium-release-activated channels are induced, promoting NFAT dephosphorylation and translocation into the nucleus. In this study, we report a progressive decrease of NFATc1 in lung tumor tissue and in tumor-infiltrating lymphocytes (TIL) of patients suffering from advanced-stage non-small cell lung cancer (NSCLC). Mice harboring conditionally inactivated NFATc1 in T cells (NFATc1ΔCD4) showed increased lung tumor growth associated with impaired T-cell activation and function. Furthermore, in the absence of NFATc1, reduced IL2 influenced the development of memory CD8+ T cells. We found a reduction of effector memory and CD103+ tissue-resident memory (TRM) T cells in the lung of tumor-bearing NFATc1ΔCD4 mice, underlining an impaired cytotoxic T-cell response and a reduced TRM tissue-homing capacity. In CD4+ICOS+ T cells, programmed cell death 1 (PD-1) was induced in the draining lymph nodes of these mice and associated with lung tumor cell growth. Targeting PD-1 resulted in NFATc1 induction in CD4+ and CD8+ T cells in tumor-bearing mice and was associated with increased antitumor cytotoxic functions. This study reveals a role of NFATc1 in the activation and cytotoxic functions of T cells, in the development of memory CD8+ T-cell subsets, and in the regulation of T-cell exhaustion. These data underline the indispensability of NFATc1 for successful antitumor immune responses in patients with NSCLC.Significance: The multifaceted role of NFATc1 in the activation and function of T cells during lung cancer development makes it a critical participant in antitumor immune responses in patients with NSCLC. Cancer Res; 78(13); 3619-33. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29691251     DOI: 10.1158/0008-5472.CAN-17-3297

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Camphor white oil induces tumor regression through cytotoxic T cell-dependent mechanisms.

Authors:  Yalda Moayedi; Sophie A Greenberg; Blair A Jenkins; Kara L Marshall; Lina V Dimitrov; Aislyn M Nelson; David M Owens; Ellen A Lumpkin
Journal:  Mol Carcinog       Date:  2019-01-20       Impact factor: 4.784

Review 2.  Precursor exhausted T cells: key to successful immunotherapy?

Authors:  Axel Kallies; Dietmar Zehn; Daniel T Utzschneider
Journal:  Nat Rev Immunol       Date:  2019-10-07       Impact factor: 53.106

Review 3.  Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.

Authors:  Mengling Wu; Qianrui Huang; Yao Xie; Xuyi Wu; Hongbo Ma; Yiwen Zhang; Yong Xia
Journal:  J Hematol Oncol       Date:  2022-03-12       Impact factor: 17.388

4.  IL-9 Producing Tumor-Infiltrating Lymphocytes and Treg Subsets Drive Immune Escape of Tumor Cells in Non-Small Cell Lung Cancer.

Authors:  Lisanne Heim; Zuqin Yang; Patrick Tausche; Katja Hohenberger; Mircea T Chiriac; Julia Koelle; Carol-Immanuel Geppert; Katerina Kachler; Sarah Miksch; Anna Graser; Juliane Friedrich; Rakshin Kharwadkar; Ralf J Rieker; Denis I Trufa; Horia Sirbu; Markus F Neurath; Mark H Kaplan; Susetta Finotto
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

5.  Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.

Authors:  A N Niemeijer; D Leung; M C Huisman; I Bahce; O S Hoekstra; G A M S van Dongen; R Boellaard; S Du; W Hayes; R Smith; A D Windhorst; N H Hendrikse; A Poot; D J Vugts; E Thunnissen; P Morin; D Lipovsek; D J Donnelly; S J Bonacorsi; L M Velasquez; T D de Gruijl; E F Smit; A J de Langen
Journal:  Nat Commun       Date:  2018-11-07       Impact factor: 14.919

Review 6.  Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer.

Authors:  Ewelina Grywalska; Marcin Pasiarski; Stanisław Góźdź; Jacek Roliński
Journal:  Onco Targets Ther       Date:  2018-10-04       Impact factor: 4.147

7.  NFAT1 and NFAT2 Differentially Regulate CTL Differentiation Upon Acute Viral Infection.

Authors:  Tianhao Xu; Ashleigh Keller; Gustavo J Martinez
Journal:  Front Immunol       Date:  2019-02-15       Impact factor: 7.561

8.  Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer.

Authors:  Lisanne Heim; Katerina Kachler; Raphaela Siegmund; Denis I Trufa; Susanne Mittler; Carol-Immanuel Geppert; Juliane Friedrich; Ralf J Rieker; Horia Sirbu; Susetta Finotto
Journal:  Br J Cancer       Date:  2019-04-08       Impact factor: 7.640

Review 9.  Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance.

Authors:  Łukasz Zadka; Damian J Grybowski; Piotr Dzięgiel
Journal:  Cell Oncol (Dordr)       Date:  2020-06-02       Impact factor: 6.730

10.  Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.

Authors:  Jin Ma; Rao Du; Yan Huang; Wen Zhong; Huan Gui; Chenmei Mao; Xiudao Song; Jun Lu
Journal:  Pathol Oncol Res       Date:  2021-04-09       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.